Evidence map›Paper›PMID 26989387›Full record

ReviewViszeralmedizin2015

Surgical Therapy of Early Carcinoma of the Esophagus.

Michael Pauthner, Thomas Haist, Markus Mann, Dietmar Lorenz

Abstract readReview
In one paragraph

Review in Viszeralmedizin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Modeling the Cost-effectiveness of Esophageal Cancer Screening in China.Cost effectiveness and resource allocation : C/E · 2020
    Article
  5. Article
  6. [Surgical strategy for early stage carcinoma of the esophagus].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael PauthnerDepartment of General and Visceral Surgery, Sana Klinikum Offenbach GmbH, Teaching Hospital of the University Medicine of Frankfurt am Main, Offenbach, Germany.
Thomas HaistDepartment of General and Visceral Surgery, Sana Klinikum Offenbach GmbH, Teaching Hospital of the University Medicine of Frankfurt am Main, Offenbach, Germany.
Markus MannDepartment of General and Visceral Surgery, Sana Klinikum Offenbach GmbH, Teaching Hospital of the University Medicine of Frankfurt am Main, Offenbach, Germany.
Dietmar LorenzDepartment of General and Visceral Surgery, Sana Klinikum Offenbach GmbH, Teaching Hospital of the University Medicine of Frankfurt am Main, Offenbach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe modern therapy of early esophageal carcinomas (pT1) requires an excellent cooperation between experienced gastroenterologists, pathologists, and esophageal surgeons. While endoscopic resection (ER) is accepted as the standard curative treatment for mucosal esophageal carcinomas, submucosal tumors are regarded as a strict indication for surgery. There is an ongoing discussion about the operative approach and the extent of lymph node dissection in these cases.

methodsA literature review was performed to evaluate the operative treatment of early esophageal cancer. In view of oncological risk factors, treatment strategies, and operative procedures, current studies are summarized and compared to the results of our own center. RESULTS AND

conclusionIn early esophageal cancer, lymph node involvement is the only independent risk factor for survival and recurrence rates. There is evidence that infiltrated lymph nodes (N+) are significantly correlated with tumor infiltration depth, lymphovascular (L1) and microvascular invasion (V1), and poor tumor differentiation (G3). Several studies suggest that early squamous cell carcinomas (eSCCs) and early adenocarcinomas (eACs) have a different tumor biology and therefore need a different treatment strategy. While eSCCs in stage m1 and m2 can be cured by ER, tumors infiltrating the submucosal layer (sm1-3) show a high rate of lymph node metastasis (LNM); thus, surgical resection (SR) is clearly indicated. In tumors with invasion into the deep mucosa (m3) the risk of LNM is up to 11%; however, reliable data are rare and the type of therapy should be discussed with the patients individually. In eACs, ER is the standard curative treatment for all mucosal tumors (m1-m4) and sm1 tumors with low-risk constellation (G1, L0, VO, R0). All high-risk sm1 tumors and those with deeper submucosal infiltration (sm2, sm3) show a high rate of LNM and require SR. The standard operative procedure for early esophageal carcinomas is an Ivor-Lewis esophagectomy with radical, at least two-field lymphadenectomy.

Indexed as

Early esophageal cancerEsophagectomyLymphadenectomyPrognostic risk factors

Identifiers

PMID26989387
PMCPMC4789960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.